Search results for: monoclonal
#32454821 2020/05/04 To Up
Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients.Denosumab is a monoclonal antibody that prevents the development of osteoclasts. The effect of denosumab in solid organ transplant recipients has been elucidated, but its effect in haematopoietic stem cell transplantation recipients has not been studied yet. The aim of this study was to determine the effectiveness and safety of denosumab in haematopoietic stem cell transplantation recipients.
Chaiho Jeong, Hee-Je Kim, Seok Lee, Moo Il Kang, Jeonghoon Ha
2815 related Products with: Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients.25 ug124 wells3 Modulators1 x 10^6 cells/vial5 ug3 5 G2ug
#32454513 2020/05/26 To Up
Human neutralizing antibodies elicited by SARS-CoV-2 infection.The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions. SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor. Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions.
Bin Ju, Qi Zhang, Jiwan Ge, Ruoke Wang, Jing Sun, Xiangyang Ge, Jiazhen Yu, Sisi Shan, Bing Zhou, Shuo Song, Xian Tang, Jinfang Yu, Jun Lan, Jing Yuan, Haiyan Wang, Juanjuan Zhao, Shuye Zhang, Youchun Wang, Xuanling Shi, Lei Liu, Jincun Zhao, Xinquan Wang, Zheng Zhang, Linqi Zhang0.1 ml100 0.1 ml1mg100 μg50025mg200ug20000 UNITS0.1 ml0.1 ml100.00 ug
#32454512 2020/05/26 To Up
A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.A
Rui Shi, Chao Shan, Xiaomin Duan, Zhihai Chen, Peipei Liu, Jinwen Song, Tao Song, Xiaoshan Bi, Chao Han, Lianao Wu, Ge Gao, Xue Hu, Yanan Zhang, Zhou Tong, Weijin Huang, William Jun Liu, Guizhen Wu, Bo Zhang, Lan Wang, Jianxun Qi, Hui Feng, Fu-Sheng Wang, Qihui Wang, George Fu Gao, Zhiming Yuan, Jinghua Yan
2857 related Products with: A human neutralizing antibody targets the receptor binding site of SARS-CoV-2.100ul100ug Lyophilized100ug Lyophilized 100ul 100ul 100ul100ug Lyophilized1-8 Sample Kit0.1 mg 100ul 100ul 100ul
No related Items
#32454402 2020/05/23 To Up
CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model.The completeness of resection is a key prognostic indicator in patients with ovarian cancer, and the application of tumour-targeted fluorescence image-guided surgery (FIGS) has led to improved detection of peritoneal metastases during cytoreductive surgery. CD24 is highly expressed in ovarian cancer and has been shown to be a suitable biomarker for tumour-targeted imaging.
Katrin Kleinmanns, Vibeke Fosse, Ben Davidson, Elvira García de Jalón, Olav Tenstad, Line Bjørge, Emmet McCormack
1624 related Products with: CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model.1 kit1 kit
#32454401 2020/05/23 To Up
CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma.The survival rate of patients with advanced high-grade serous ovarian carcinoma (HGSOC) remains disappointing. Clinically translatable orthotopic cell line xenograft models and patient-derived xenografts (PDXs) may aid the implementation of more personalised treatment approaches. Although orthotopic PDX reflecting heterogeneous molecular subtypes are considered the most relevant preclinical models, their use in therapeutic development is limited by lack of appropriate imaging modalities.
Katrin Kleinmanns, Katharina Bischof, Shamundeeswari Anandan, Mihaela Popa, Lars A Akslen, Vibeke Fosse, Ida Tveit Karlsen, Bjørn T Gjertsen, Line Bjørge, Emmet McCormack
2024 related Products with: CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma.
Error loading info... Pleas try again later.
Error loading info... Pleas try again later.
#32453570 2020/05/26 To Up
Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting.Most of the current FDA and EMA approved therapeutic monoclonal antibodies (mAbs) are based on humanized or human IgG1, 2 or 4 subclasses and engineered variants. On the structural side, these subclasses are characterized by specific inter-chains disulfide bridge connections. Different analytical techniques have been reported to assess intact IgGs subclasses, with recently special interest in native ion mobility (IM) and collision induced unfolding (CIU) mass spectrometry (MS). However, these two techniques exhibit significant limitations to differentiate mAb subclasses at the intact level. In the present work, we aimed at developing a unique IM-MS-based approach for the characterization of mAb subclasses at the middle level. Upon IdeS-digestion, the unfolding patterns of the F(ab')2 and Fc domains were simultaneously analyzed in a single run to provide deeper structural insights of the mAb scaffold. The unfolding patterns associated with the F(ab')2 domains are com-pletely different in terms of unfolding energies and number of transitions. Thereby, F(ab')2 regions are the diagnostic domain to provide specific unfolding signatures to differentiate IgG subclasses and provide more confident subclass categorization than CIU on intact mAbs. In addition, the potential of middle-level CIU was evaluated through the characterization of ecu-lizumab, a hybrid therapeutic IgG2/4 mAb. The unfolding signatures of both domains allowed to corroborate, within a single run, the hybrid nature of eculizumab as well as specific subclass domain assignments to the F(ab')2 and Fc regions. Alto-gether, our results confirm the suitability of middle-level CIU of F(ab')2 domains for subclass categorization of canonical and more complex new generation engineered antibodies and related products.
Thomas Botzanowski, Oscar Hernandez-Alba, Martine Malissard, Elsa Wagner-Rousset, Evolène Deslignière, Olivier Colas, Jean-François Haeuw, Alain Beck, Sarah Cianférani
1910 related Products with: Middle level IM-MS and CIU experiments for improved therapeutic immunoglobulin subclass fingerprinting.10 mg 100ul100μg 100ul10 ml 125 ml 0.1 mg500 MG100ug Lyophilized1 mg
#32453136 2020/05/19 To Up
ADAM17-EGFR signaling contributes to oral cancer pain.Cancer cells secrete pro-nociceptive mediators that sensitize adjacent sensory neurons and cause pain. Identification and characterization of these mediators could pinpoint novel targets for cancer pain treatment. In the present study we identified candidate genes in cancer cell lines that encode for secreted or cell surface proteins that may drive nociception. To undertake this work, we utilized an acute cancer pain mouse model, transcriptomic analysis of publicly available human tumor-derived cell line data, and a literature review. Cancer cell line supernatants were assigned a phenotype based on evoked nociceptive behavior in an acute cancer pain mouse model. We compared gene expression data from nociceptive and non-nociceptive cell lines. Our analyses revealed differentially expressed genes (DEGs) and pathways; many of the identified genes were not previously associated with cancer pain signaling. Epidermal growth factor receptor (EGFR) and disintegrin metalloprotease domain 17 (ADAM17) were identified as potential targets among the DEGs. We found that the nociceptive cell lines contained significantly more ADAM17 protein in the cell culture supernatant compared to non-nociceptive cell lines. Cytoplasmic EGFR was present in almost all (>90%) tongue primary afferent neurons in mice. Monoclonal antibody against EGFR, cetuximab, inhibited cell line supernatant-induced nociceptive behavior in an acute oral cancer pain mouse model. We infer from these data that ADAM17-EGFR signaling is involved in cancer mediator-induced nociception. The differentially expressed genes and their secreted protein products may serve as candidate therapeutic targets for oral cancer pain and warrant further evaluation.
Nicole N Scheff, Yi Ye, Zachary Conley, Jen Wui Quan, Yat Vong Ronald Lam, Richard Klares, Kamalpreet Singh, Brian L Schmidt, Bradley E AouizeratOne 96-Well Strip MicroplOne 96-Well Strip MicroplOne 96-Well Strip MicroplOne 96-Well Strip Micropl14 inhibitors
#32452309 2020/04/16 To Up
Biosimilars of monoclonal antibodies in inflammatory diseases and cancer: current situation, challenges, and opportunities.The approval pathway for biosimilars of monoclonal antibodies in the European Union is aimed at ruling out the presence of significant differences with the original biological in quality attributes, efficacy, immunogenicity and safety. It also provides the rationale for extrapolating the evidence obtained with a biosimilar in at least one indication to the rest of the approved indications of its original biological, thus simplifying the development programme of biosimilars. Biosimilars of monoclonal antibodies available in the European Union for the treatment of inflammatory diseases and cancer have fulfilled all the requirements for approval, and many of them have additional evidence available. Moreover, real world data confirms the safety and efficacy of these drugs in the indications they are being used for. In Spain, many scientific societies endorse the regulatory pathway of biosimilars and acknowledge their role in the efficiency of the healthcare system. Even so, some barriers remain that limit their use. The implementation of different measures at the patient, prescriber, institutional, and national levels might increase the penetration of biosimilars, freeing up resources that may be invested in other therapies and, potentially, boost innovation.
Miguel Ángel Calleja-Hernández, José Manuel Martínez-Sesmero, Belén Santiago-Josefat
1241 related Products with: Biosimilars of monoclonal antibodies in inflammatory diseases and cancer: current situation, challenges, and opportunities.100.00 ug100.00 ug100.00 ug1000 TESTS/0.65ml100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug100.00 ug
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia